RLX Q1 Results: Major Drop Seen

MarketBusiness by Leona Zhu, Ellesmere Zhu

May.17.2023

RLX Q1 Results: Major Drop Seen

RLX Technology reports significant revenue drop and net loss for Q1 2023, compared to 2022.

On May 17, RLX Technology (NYSE: RLX) released its financial results for the first quarter of 2023 ending on March 31st.

The report revealed a net revenue of CNY 188.9 million (approximately USD 27.5 million), a drastic drop of 89% compared to the same period last year, which stood at CNY 1.7145 billion.

The company also suffered a net loss of CNY 56.3 million (approximately USD 8.2 million), a significant downturn from the net profit of CNY 687.1 million in Q1 of 2022.

Thumbnail source: Bloomberg

Also Read:

[1] Flavored Vapes Crucial for Adult Smokers' Transition, Says Relx

[2] RELX Leads in Patents: 900 Global Applications

[3] RELX: German Market to See Further Growth

[4] RELX Sees 10% Growth in Middle East and North Africa Markets

[5] RELX Vapes Seized by Regulator Possibly due to Incomplete Docs

[6] What's Behind RELX's Monthly 76% Stock Gains?

[7] RELX Pixel Debuts in Indonesia

[8] RELX Launches New Pod Device in Indonesia

#North America #United States #Disposable e-cigarettes #Regulation

*This article is an original article of 2FIRSTS Technology Co., Ltd. The copyright and license rights belong to the company. Any entity or individual shall make link and credit 2FIRSTS when taking actions to copy, reprint or distribute the original article. The company retains the right to pursue its legal responsibility.

China Tobacco Regulation Shift：Policy Updates and Market Impact

China Tobacco Regulation Shift：Policy Updates and Market Impact

EVO NXT European Tobacco & NGP Exhibition

EVO NXT European Tobacco & NGP Exhibition

Imperial Brands Pulls myblu Vape Business From U.S., Citing Prolonged FDA Approval Process

Imperial Brands Pulls myblu Vape Business From U.S., Citing Prolonged FDA Approval Process

Imperial Brands said it will phase out its myblu vaping business in the United States, citing prolonged FDA approval timelines for new vape products. The company said it will instead focus on modern oral nicotine products in the U.S., including the expansion of its Zone brand and new flavors. While overall next-generation product revenue continued to grow, revenue from the category in the Americas declined sharply.

BAT Shares Surge Nearly 6% as FDA Policy Shift Eases Pressure on Vuse and Velo

BAT Shares Surge Nearly 6% as FDA Policy Shift Eases Pressure on Vuse and Velo

British American Tobacco (BAT) shares rose sharply on May 12 after the U.S. Food and Drug Administration signaled it would deprioritize enforcement against certain unauthorized e-cigarette and nicotine pouch products with accepted premarket applications. Investors viewed the move as favoring established players such as BAT’s Vuse and Velo brands.

Zyn Emerges as MAGA Cultural Symbol Amid FDA Policy Shift

Zyn Emerges as MAGA Cultural Symbol Amid FDA Policy Shift

According to The Wall Street Journal, nicotine pouch brand Zyn has rapidly gained popularity across the Trump administration and conservative political circles, including among U.S. Health Secretary Robert F. Kennedy Jr.

Bloomberg: Zyn’s Dry-Mouth Problem Threatens Its Hold on Nicotine Pouch Market

Bloomberg: Zyn’s Dry-Mouth Problem Threatens Its Hold on Nicotine Pouch Market

According to Bloomberg, Philip Morris International’s Zyn is facing growing competition in the U.S. nicotine pouch market as consumers shift toward moister alternatives such as British American Tobacco’s Velo Plus.

Exclusive | TPE 2026 Cools as Caution Deepens in the U.S. Vape Market

Exclusive | TPE 2026 Cools as Caution Deepens in the U.S. Vape Market

The show had become an important check-in point for Chinese manufacturers and brand owners looking for signs of change in the U.S. market after months of softer demand. Instead, participants said the event highlighted a more restrained mood: traffic in the vape section was uneven, standout launches were limited, and conversations often failed to turn into orders.

Special Report｜Haypp’s Nicotine Pouch Volumes Rise 40%: Who Controls the Digital Shelf for Modern Oral?

Special Report｜Haypp’s Nicotine Pouch Volumes Rise 40%: Who Controls the Digital Shelf for Modern Oral?

Haypp Group reported a 40% year-on-year increase in nicotine pouch volumes in the first quarter of 2026, with U.S. and U.K. volumes rising 123% and 102%, respectively. Haypp says around 97% of its consumer traffic is organic and that its Media & Insights business provides brand owners with on-site visibility, trial activation and consumer intelligence. For international tobacco companies, Haypp may be both a growth partner for modern oral products and a new source of channel leverage.

Related Topics

Related Read

Imperial Brands Pulls myblu Vape Business From U.S., Citing Prolonged FDA Approval Process

Imperial Brands Pulls myblu Vape Business From U.S., Citing Prolonged FDA Approval Process

BAT Shares Surge Nearly 6% as FDA Policy Shift Eases Pressure on Vuse and Velo

BAT Shares Surge Nearly 6% as FDA Policy Shift Eases Pressure on Vuse and Velo

Zyn Emerges as MAGA Cultural Symbol Amid FDA Policy Shift

Zyn Emerges as MAGA Cultural Symbol Amid FDA Policy Shift

Bloomberg: Zyn’s Dry-Mouth Problem Threatens Its Hold on Nicotine Pouch Market

Bloomberg: Zyn’s Dry-Mouth Problem Threatens Its Hold on Nicotine Pouch Market

Exclusive | TPE 2026 Cools as Caution Deepens in the U.S. Vape Market

Exclusive | TPE 2026 Cools as Caution Deepens in the U.S. Vape Market

Special Report｜Haypp’s Nicotine Pouch Volumes Rise 40%: Who Controls the Digital Shelf for Modern Oral?

Special Report｜Haypp’s Nicotine Pouch Volumes Rise 40%: Who Controls the Digital Shelf for Modern Oral?